Suchergebnisse - "Babiker, Hani M"

PubPharm (93)

1

A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study)

enthalten in: The oncologist | 2023

von Babiker, H. | Kay, M. | Stuehm, C. | +2

2

A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma

enthalten in: Expert opinion on drug safety | 2023

von Uson, P. | Bearss, J. | Babiker, H. | +1

3

Targeting leukemia inhibitory factor in pancreatic adenocarcinoma

enthalten in: Expert opinion on investigational drugs | 2023

von Wang, J. | Karime, C. | Majeed, U. | +3

4

An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment : The Role of Circulating Tumor DNA Testing

enthalten in: Cureus | 2023

von Anisetti, B. | Coston, T. | Ahmed, A. | +4

5

Novel precision therapies for cholangiocarcinoma : an overview of clinical trials

enthalten in: Expert opinion on investigational drugs | 2023

von Uson Junior, P. | Bearss, J. | Babiker, H. | +1

6

Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer : Toxicity, Disease Control, and Survival Outcomes

enthalten in: International journal of particle therapy | 2023

von Rutenberg, M. | Hoppe, B. | Starr, J. | +13

7

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA

enthalten in: Frontiers in oncology | 2022

von Swami, U. | Zimmerman, R. | Nussenzveig, R. | +18

8

Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary

enthalten in: JCO precision oncology | 2021

von Martinez, F. | Brucks, E. | Otsuji, J. | +4

9

Contemporary Management of Pancreatic Cancer from an Internist Perspective

enthalten in: The American journal of medicine | 2021

von Sipra, Q. | Islam, M. | Riaz, I. | +4

10

Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein

enthalten in: Journal of clinical pharmacology | 2021

von Zahir, H. | Kobayashi, F. | Zamora, C. | +6

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]